Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PTC Therapeutics -- PTCT -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2)	1/24/2014 1:10:56 PM
From: tuck	Read Replies (2) \| Respond to of 38

Good warning as EMA says no: EMA says no to ataluren Company has said it will appeal in hopes of submitting a confirmatory study based on further enrollment because the walking distance numbers are claimed to be good. Stock is holding up well under the circumstances. I wouldn't expect that they're in any better shape with the FDA. The BMI-1 program you point to is preclinical. You know that, of course, just putting it out there with the thought that it's worth watching, with plenty of time on the clock. Know nothing of competing programs for that target. Their candidate phosphorylates BMI-1, thus deactivating it. Apparently, BMI-1 expresses only on carcinogenic stem cells, so toxicity is expected to be slight. So far, a few xenograft mice have done OK on it, FWIW. pipeline Cheers, Tuck